Modified expi293 cell culture system using piggyBac transposon enables efficient production of human FVIII.
Int J Hematol
; 117(1): 56-67, 2023 Jan.
Article
in En
| MEDLINE
| ID: mdl-36229740
ABSTRACT
Human blood coagulation factor VIII (hFVIII) is used in hemostatic and prophylactic treatment of patients with hemophilia A. Biotechnological innovations have enabled purification of the culture medium of rodent or human cells harboring the hFVIII expression cassette. However, cell lines express hFVIII protein derived from an exogenous expression vector at a lower level than most other proteins. Here, we describe hFVIII production using piggyBac transposon and the human-derived expi293F cell line. Use of a drug selection protocol, rather than transient expression protocol, allowed cells harboring hFVIII expression cassettes to efficiently produce hFVIII. In heterogeneous drug-selected cells, the production level was maintained even after multiple passages. The specific activity of the produced hFVIII was comparable to that of the commercial product and hFVIII derived from baby hamster kidney cells. We also applied codon optimization to the hFVIII open reading frame sequences in the transgene, which increased production of full-length hFVIII, but decreased production of B-domain-deleted human FVIII (BDD-hFVIII). Low transcriptional abundance of the hF8 transgene was observed in cells harboring codon-optimized BDD-hFVIII expression cassettes, which might partially contribute to decreased hFVIII production. The mechanism underlying these distinct outcomes may offer clues to highly efficient hFVIII protein production.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Factor VIII
/
Genetic Therapy
/
Cell Culture Techniques
/
Hemophilia A
Type of study:
Guideline
Limits:
Animals
/
Humans
Language:
En
Journal:
Int J Hematol
Journal subject:
HEMATOLOGIA
Year:
2023
Document type:
Article
Affiliation country:
Japan